Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arne Hansen

Showing results (101-110 of 132) with videos related to

Pageof 14
Sort By:
Clinical Epigenetics|June 13, 2019
DNA methylation profiling allows for characterization of atrial and ventricular cardiac tissues and hiPSC-CMsKirstin Hoff, Marta Lemme, Anne-Karin Kahlert, et al.
Circulation|September 5, 2020
An Important Role for DNMT3A-Mediated DNA Methylation in Cardiomyocyte Metabolism and ContractilityAlexandra Madsen, Grit Höppner, Julia Krause, et al.
Stem Cell Reports|October 14, 2020
Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue FormatIngra Mannhardt, Umber Saleem, Diogo Mosqueira, et al.
Stem Cell Reports|May 24, 2016
Human Engineered Heart Tissue: Analysis of Contractile ForceIngra Mannhardt, Kaja Breckwoldt, David Letuffe-Brenière, et al.
British Journal of Pharmacology|February 23, 2026
Higher sensitivity to ouabain-induced toxicity in human induced pluripotent stem cell-derived cardiomyocytes than human adult heart tissue despite similar Na<sup>+</sup>/K<sup>+</sup>-ATPase pump current amplitudesDjemail Ismaili, Paavo Virtanen, Junsoo Im, et al.
Human Molecular Genetics|April 12, 2013
Heterozygous LmnadelK32 mice develop dilated cardiomyopathy through a combined pathomechanism of haploinsufficiency and peptide toxicityMarie-Elodie Cattin, Anne T Bertrand, Saskia Schlossarek, et al.
European Heart Journal|May 10, 2018
CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathyDiogo Mosqueira, Ingra Mannhardt, Jamie R Bhagwan, et al.
Nature Protocols|May 12, 2017
Differentiation of cardiomyocytes and generation of human engineered heart tissueKaja Breckwoldt, David Letuffe-Brenière, Ingra Mannhardt, et al.
Human Molecular Genetics|April 24, 2012
Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathyFelix W Friedrich, Brendan R Wilding, Silke Reischmann, et al.
Nature Protocols|August 7, 2019
Author Correction: Differentiation of cardiomyocytes and generation of human engineered heart tissueKaja Breckwoldt, David Brenière-Letuffe, Ingra Mannhardt, et al.
Pageof 14

Showing results (101-110 of 132) with videos related to

Sort By:
Pageof 14
Clinical Epigenetics|June 13, 2019
DNA methylation profiling allows for characterization of atrial and ventricular cardiac tissues and hiPSC-CMsKirstin Hoff, Marta Lemme, Anne-Karin Kahlert, et al.
Circulation|September 5, 2020
An Important Role for DNMT3A-Mediated DNA Methylation in Cardiomyocyte Metabolism and ContractilityAlexandra Madsen, Grit Höppner, Julia Krause, et al.
Stem Cell Reports|October 14, 2020
Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue FormatIngra Mannhardt, Umber Saleem, Diogo Mosqueira, et al.
Stem Cell Reports|May 24, 2016
Human Engineered Heart Tissue: Analysis of Contractile ForceIngra Mannhardt, Kaja Breckwoldt, David Letuffe-Brenière, et al.
British Journal of Pharmacology|February 23, 2026
Higher sensitivity to ouabain-induced toxicity in human induced pluripotent stem cell-derived cardiomyocytes than human adult heart tissue despite similar Na<sup>+</sup>/K<sup>+</sup>-ATPase pump current amplitudesDjemail Ismaili, Paavo Virtanen, Junsoo Im, et al.
Human Molecular Genetics|April 12, 2013
Heterozygous LmnadelK32 mice develop dilated cardiomyopathy through a combined pathomechanism of haploinsufficiency and peptide toxicityMarie-Elodie Cattin, Anne T Bertrand, Saskia Schlossarek, et al.
European Heart Journal|May 10, 2018
CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathyDiogo Mosqueira, Ingra Mannhardt, Jamie R Bhagwan, et al.
Nature Protocols|May 12, 2017
Differentiation of cardiomyocytes and generation of human engineered heart tissueKaja Breckwoldt, David Letuffe-Brenière, Ingra Mannhardt, et al.
Human Molecular Genetics|April 24, 2012
Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathyFelix W Friedrich, Brendan R Wilding, Silke Reischmann, et al.
Nature Protocols|August 7, 2019
Author Correction: Differentiation of cardiomyocytes and generation of human engineered heart tissueKaja Breckwoldt, David Brenière-Letuffe, Ingra Mannhardt, et al.
Pageof 14